. 2024 Jan 10;15(2):250–257. doi: 10.1021/acsmedchemlett.3c00498

Table 1. Inhibitory Activity of Ligand 1′, PROTACs 1 and 2,^a and of Representative SARS-CoV-2 Inhibitors against 3CL^Pro.

compd	IC₅₀ (μM)
Ligand 1′	1.35 ± 0.34
PROTAC 1	21.2 ± 5.8
PROTAC 2	N/A
representative 3CL^Proinhibitors	reported IC₅₀ (μM)
GC-376^41,44,45	0.19 ± 0.04
GC-373⁴⁵	0.40 ± 0.05
Nirmatrelvir⁴⁶	0.051 ± 0.01
Boceprevir^47,48	5.40 ± 1.53
Dalcetrapib-thiol⁴⁹	14.4 ± 3.3

Mean from three different assays, errors were in the range of 5–10% of the reported values; IC₅₀ values were retrieved from dose–response assays as the concentration of compound required for 50% inhibition, as estimated by nonlinear correlation using GraphPad Prism software.

Table 1. Inhibitory Activity of Ligand 1′, PROTACs 1 and 2,a and of Representative SARS-CoV-2 Inhibitors against 3CLPro.

Table 1. Inhibitory Activity of Ligand 1′, PROTACs 1 and 2,^a and of Representative SARS-CoV-2 Inhibitors against 3CL^Pro.